全文获取类型
收费全文 | 799篇 |
免费 | 37篇 |
国内免费 | 4篇 |
学科分类
医药卫生 | 840篇 |
出版年
2023年 | 11篇 |
2022年 | 11篇 |
2021年 | 20篇 |
2020年 | 12篇 |
2019年 | 15篇 |
2018年 | 29篇 |
2017年 | 24篇 |
2016年 | 22篇 |
2015年 | 20篇 |
2014年 | 29篇 |
2013年 | 34篇 |
2012年 | 76篇 |
2011年 | 79篇 |
2010年 | 42篇 |
2009年 | 49篇 |
2008年 | 53篇 |
2007年 | 72篇 |
2006年 | 63篇 |
2005年 | 55篇 |
2004年 | 47篇 |
2003年 | 31篇 |
2002年 | 20篇 |
2001年 | 3篇 |
2000年 | 1篇 |
1999年 | 2篇 |
1998年 | 7篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1990年 | 1篇 |
1988年 | 3篇 |
1986年 | 1篇 |
1979年 | 1篇 |
排序方式: 共有840条查询结果,搜索用时 15 毫秒
11.
Vasileios Peppes George Rammos Efstathios Manios Eleni Koroboki Stylianos Rokas Nikolaos Zakopoulos 《Clinical Interventions in Aging》2008,3(4):699-710
Background
Our objective was to associate serum levels of myocardial enzymes and inflammatory biomarkers with severity of coronary artery disease (CAD).Patients and methods
123 patients participated in our study, including 65 cases of acute myocardial infarction (MI), 27 cases of newly diagnosed CAD – without MI – and 31 controls. In all subjects, myocardial serum enzyme levels (creatine phosphokinase, aspartate aminotransferase, lactate dehydrogenase) and inflammatory indices (C-reactive protein, fibrinogen, white blood cells, and erythrocyte sedimentation rate) were measured. Patients were all submitted to coronary angiography and CAD severity was evaluated by Gensini score.Results
Significant differences concerning enzyme serum levels and inflammatory indices were found to exist between the three study groups, being highest among patients with acute MI (p < 0.001). A significant association was demonstrated between Gensini score and serum enzyme levels as well as inflammatory biomarkers.Conclusions
Our findings suggest that serum levels of myocardial enzymes and inflammatory indices correlate with CAD severity in Greek patients. 相似文献12.
Kyriakides ZS Psychari S Iliodromitis EK Kolettis TM Sbarouni E Kremastinos DT 《Chest》2002,121(4):1211-1215
BACKGROUND: Controversy exists regarding inhibition of ischemic preconditioning in hyperlipidemic animals. In this study, we tested the hypothesis that hyperlipidemia inhibits the normal reduction of myocardial ischemia on repeated balloon inflations (BIs) during angioplasty. METHODS: We studied 33 patients undergoing coronary angioplasty. All underwent a minimum of three BIs. Patients were grouped according to the following plasma cholesterol levels: 13 patients had total cholesterol levels < 200 mg/dL (the normal cholesterol group); and 20 patients had total cholesterol levels > or = 200 mg/dL (the elevated cholesterol group). Surface ST-segment elevations were recorded at the end of each BI. RESULTS: In the normal cholesterol group, the mean (+/- SD) ST-segment elevation decreased from 0.21 +/- 0.15 mV during the first BI to 0.11 +/- 0.11 mV during the third BI (p < 0.05). In the elevated cholesterol group, the respective decrease was from 0.18 +/- 0.16 to 0.14 +/- 0.15 mV (p = not significant) [between-group comparisons: F = 3.97; p = 0.02]. The decrease in ST-segment elevation was correlated with the total cholesterol levels (r = -0.48; p = 0.005), the low-density lipoprotein (LDL) cholesterol levels (r = -0.50; p = 0.003), and the high-density lipoprotein/LDL levels (r = 0.44; p = 0.01). CONCLUSION: Hyperlipidemia prevents the normal reduction of myocardial ischemia on repeated BIs during angioplasty. This leads to the clinical implication that reduction of cholesterol plasma levels, apart from its other known benefits, could also have a beneficial effect on cardioprotection. 相似文献
13.
Flora Zagouri Evangelos Terpos Efstathios Kastritis Meletios-Athanasios Dimopoulos 《Expert opinion on pharmacotherapy》2015,16(12):1865-1877
Introduction: Lenalidomide, an immunomodulatory agent with unique mechanism of action, represents the cornerstone in the treatment of patients with multiple myeloma (MM) providing rapid and sustained control of the disease with a manageable safety profile.Areas covered: This review article, synthesizing all available data coming from trials and evaluating the efficacy and safety of lenalidomide in patients with MM, tries to provide to the clinicians with an easy-to-grasp synopsis of recent and clinically meaningful advances on the field.Expert opinion: Lenalidomide combined with dexamethasone is a safe and effective option for newly diagnosed MM patients ineligible for autologous stem cell transplantation (ASCT). Long-term administration of the agent as continuous treatment for ineligible for ASCT patients or maintenance therapy after ASCT has documented unprecedented progression-free survival improvements, whereas lenalidomide in combination with dexamethasone has shown deep and durable remissions for patients with relapsed and/or refractory disease. 相似文献
14.
Anna Theodorou-Kanakari Spyridon Karampitianis Vasiliki Karageorgou Eleni Kampourelli Efstathios Kapasakis Panagiotis Theodossiadis Irini Chatziralli 《Advances in therapy》2018,35(10):1510-1518
Introduction
The purpose of this review is to present the current and emerging treatment alternatives for Leber’s hereditary optic neuropathy (LHON), emphasizing the most recent use of idebenone and stem cells or gene therapy.Methods
A comprehensive literature review was performed at the PubMed database regarding the various treatment modalities for LHON.Results
Treatment modalities for LHON include nutritional supplements, activators of mitochondrial biogenesis, brimonidine, and symptomatic and supportive treatment, but nowadays attention is being paid to idebenone and gene therapy or stem cells.Conclusion
The treatment of LHON remains challenging, given the nature of the disease and its prognosis.15.
Neuromuscular diseases and their cardiac manifestations under the spectrum of cardiovascular imaging
Alexandridis Georgios M. Pagourelias Efstathios D. Fragakis Nikolaos Kyriazi Maria Vargiami Efthymia Zafeiriou Dimitrios Vassilikos Vassilios P. 《Heart failure reviews》2022,27(6):2045-2058
Heart Failure Reviews - Neuromuscular diseases (NMDs) include a broad spectrum of disorders that affect motor unit in every possible site, extending from the cell body of peripheral nerves to the... 相似文献
16.
Zenon S. Kyriakides Eftihia Sbarouni Aias Antoniadis Efstathios K. Iliodromitis Dimitrios Mitropoulos Dimitrios T. Kremastinos 《Clinical cardiology》1998,21(10):737-742
Background and hypothesis: In vitro studies have shown that atrial natriuretic peptide (ANP) causes relaxation of pre-constricted blood vessel strips and inhibits the contraction of isolated vessels in response to norepinephrine and angiotensin II. The present study examined the effects of exogenous ANP on the coronary collateral blood flow during angioplasty. Methods: We studied 15 patients undergoing elective balloon angioplasty during the second and third balloon inflations. A Doppler flow guidewire was advanced distal to the lesion and used for the estimation of coronary blood flow velocity. After the second balloon inflation, 25 ng/kg/min of ANP were administered intracoronarily for 8 min. Electrocardiogram, pressure, and flow velocity were recorded immediately before each balloon deflation. Fourteen other patients served as controls and received normal saline infusion. Results: Velocity time integral increased from 65 ± 40 to 79 ± 46 mm (p < 0.05) during the third balloon inflation, whereas ST deviation decreased from 1.3 ± 0.9 to 0.7 ± 1.0 mV (p< 0.05). These variables did not change in the control group during the two tested balloon inflations. Conclusion: Exogenous ANP augments coronary collateral blood flow and ameliorates myocardial ischemia during angioplasty. 相似文献
17.
Efstathios T. Detorakis Kostas Perisinakis Eleni Drakonaki Dimitrios Liakopoulos Antonios Tzedakis Efrosini Papadaki Miltiadis K. Tsilimbaris 《Brachytherapy》2021,20(4):828-834
PurposeBrachytherapy with Ru-106 is widely used for the treatment of intraocular tumors, and its efficacy depends on the accuracy of radioactive plaque placement. Ru-106 plaques are MRI incompatible and create severe metal artifacts on conventional CT scans. Dual-energy CT scans (DECT) may be used to suppress such artifacts. This study examines the possibility of creating fusion images from MRI scans (preoperatively) and DECT scans (with the plaque in place) as a tool for confirming the anatomic accuracy of plaque placement.Methods and MaterialsSix patients with intraocular lesions (5 with choroidal melanoma and 1 with a retinal vasoproliferative lesion) were included. Fusion images of preoperative MRI scans and DECT scans with the plaque in place were created with the Demo version of the ImFusion suite (ImFusion GmbH, Munchen Germany). Clearance margins between the tumor and plaque edge in axial, transverse, and coronal planes as well as the elevation of the posterior plaque edge from the sclera were recorded and associated with the location of the lesion.ResultsPlaque-tumor clearance margins for transverse, sagittal, and coronal planes were higher for anteriorly located lesions (5.13 mm ± 0.11 [5.0–5.2], 5.10 mm ± 0.26 [4.9–5.4], and 5.33 mm ± 0.45 [4.9–5.8] respectively) than for posteriorly located lesions (4.16 mm ± 1.44 [2.5–5.1], 4.13 mm ± 1.42 [2.5–5.1], and 4.2 mm ± 1.21 [2.8–5.0], respectively). The elevation of the posterior plaque edge from the sclera was 0.33 mm ± 0.28 [0–0.5] and 0.63 mm ± 0.60 [0.7–1.2] for posterior and anterior lesions, respectively.ConclusionsFusion images between DECT and MRI scans may be used as a tool to confirm the accuracy of Ru-106 plaque placement in relation with the intraocular tumors in ophthalmic brachytherapy. 相似文献
18.
Gavriatopoulou Maria Ntanasis-Stathopoulos Ioannis Korompoki Eleni Fotiou Despina Migkou Magdalini Tzanninis Ioannis-Georgios Psaltopoulou Theodora Kastritis Efstathios Terpos Evangelos Dimopoulos Meletios A. 《Clinical and experimental medicine》2021,21(2):167-179
Clinical and Experimental Medicine - The new type of coronavirus (COVID-19), SARS-CoV-2 originated from Wuhan, China and has led to a worldwide pandemic. COVID-19 is a novel emerging infectious... 相似文献
19.
Makatsoris T Kalofonos HP Aravantinos G Papadimitriou C Kastritis E Rigatos SK Xiros N Petsas T Economopoulos T Sakadamis AK Fountzilas G;Hellenic Cooperative Oncology Group 《Journal of gastrointestinal cancer》2005,35(2):103-109
Background: Capecitabine and oxaliplatin are both effective and well-tolerated monotherapies for the treatment of advanced colorectal
cancer (CRC). Oxaliplatin has also been shown to be very effective when combined with 5-FU/LV in the first-line setting.
Aim of the Study: Assess the efficacy and safety of capecitabine plus oxaliplatin (XELOX) in patients with previously untreated advanced CRC.
Methods: Fifty-three patients with measurable disease received capecitabine 1,000 mg/m2 twice daily on d 1–14 and oxaliplatin 130 mg/m2 on d 1, every 3 wk. Of these, 52 were evaluable for safety and 49 for antitumor response.
Results: There was a low rate of grade 1/2 adverse events; grade 3/4 events included leukopenia (10%), neutropenia (6%), thrombocytopenia
(2%), nausea/vomiting (4%), and diarrhea (4%). The overall response rate was 39% (95% CI, 25–54%) and median time to disease
progression was 7.8 mo.
Conclusions: XELOX is an active and well-tolerated first-line treatment for advanced CRC. Randomized phase III studies are ongoing to
compare XELOX with FOLFOX in view of the comparable efficacy and safety but superior convenience of XELOX therapy.
Presented in part at the 39th American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 31–June 3, 2003. 相似文献
20.
Ioanna Xanthopoulou Vasiliki-Maria Dragona Periklis Davlouros Costas Tsioufis Efstathios Iliodromitis Dimitrios Alexopoulos for the GRAPE-AF Investigators 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2018,32(2):191-196